slp peptide Synthetic long peptides (SLPs - SLU-PP-332peptide Thirty-three unique peptides from 10 SLPs

SLU-PP-332peptide Synthetic long peptides (SLPs) represent a significant advancement in therapeutic peptide development. These molecules, typically ranging from 20 to 35 amino acids in length, are designed to elicit targeted immune responses, making them promising candidates for a variety of medical applications, particularly in cancer immunotherapy and the treatment of chronic infections. The ease of manufacturing synthetic peptides, such as those used in SLP technology, contributes to their growing importance in biomedical research and clinical development.

The Role of Synthetic Long Peptides in Immunotherapy

Synthetic long peptides (SLPs) are engineered to act as potent immunogens. By mimicking natural antigens, they can stimulate specific immune cells, such as T cells, to recognize and attack disease-related targetsThe blocking peptide binds and 'blocks' Anti-STOML2/SLP-2 primary antibody, this makes it a good negative reagent control to help confirm antibody specificity.. This approach is particularly valuable in cancer treatment, where SLP-based vaccines aim to activate the immune system against tumor-associated antigens.Vaccination with synthetic long peptide formulated with CpG in ... For instance, SLP vaccines derived from cancer-associated antigens hold great promise for stimulating anti-tumor immunity. Similarly, SLPs are being explored for their potential in treating chronic infections by eliciting robust immune responses against persistent pathogens.Apeptidevaccine consisting of 10 synthetic longpeptides(SLPs), 25-30 amino acids in size and derived from the middle portion of p53 (amino acids 70-251) ...

Applications in Cancer and Infectious Disease Treatment

The versatility of synthetic long peptides is evident in their diverse applications. In oncology, personalized SLP vaccines are being developed, tailored to an individual's specific tumor neoantigens. These vaccines, often consisting of multiple overlapping synthetic long peptides, aim to generate a broad immune response against cancer cells. Research has also explored SLP vaccination for specific conditions, such as HPV16-induced gynecological cancers, where SLP vaccines have demonstrated the ability to induce significant T-cell responses. Beyond cancer, synthetic long peptide (SLP) vaccination is a promising strategy for managing chronic viral infections, such as hepatitis B virus (HBV).

Advancements and Future Directions

Ongoing research continues to refine SLP technology. Innovations include conjugating synthetic long peptides with immune-stimulating molecules, such as Toll-like receptor (TLR) ligands, to enhance their immunogenicity and efficacy. For example, chemical conjugates comprising synthetic TLR ligands bound to antigenic synthetic long peptides are being investigated for their improved therapeutic potential.作者：MIE van Poelgeest·2013·被引用次数：235—Recently, we developed a highly immunogenicsynthetic long peptide (SLP) vaccine, consisting of long overlapping peptides of the E6 and E7 ... Furthermore, the development of multivalent synthetic long peptide (SLP) vaccines, containing multiple cytotoxic T-lymphocyte (CTL) epitopes, aims to broaden the immune attack against disease targets. The ability to synthesize these peptides with precision and at scale, as exemplified by SLP technology, underpins their future as a cornerstone of advanced immunotherapiesHPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial..